Collectively, SHP2 and XIAP are potential synthetic lethal partners, and embelin warrants further development as a novel therapeutic option for alleviating KRAS‐mutant NSCLC by cotargeting SHP2 and XIAP. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.